Skip to main content
Top
Published in: Diabetologia 1/2020

Open Access 01-01-2020 | Alzheimer's Disease | Review

Cognitive dysfunction in diabetes: how to implement emerging guidelines

Authors: Geert J. Biessels, Rachel A. Whitmer

Published in: Diabetologia | Issue 1/2020

Login to get access

Abstract

Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognised as an important comorbidity and complication of diabetes that affects an individual’s well-being and diabetes management, and is associated with diabetes treatment-related complications. Recent guidelines therefore recommend screening for cognitive impairment in older individuals with diabetes. In addition, these guidelines suggest that glucose-lowering treatment should be tailored in those diagnosed with cognitive impairment, to reduce the risk of hypoglycaemia and improve treatment adherence. This review gives an overview of cognitive dysfunction in people with diabetes, briefly describing the clinical features of different stages of cognitive dysfunction and their epidemiology. In particular, it addresses essential additional steps that need to be taken to fully implement the emerging guidelines on screening and management of cognitive dysfunction in diabetes into daily practice.
Literature
2.
go back to reference International Diabetes Federation (IDF) (2017) IDF diabetes atlas, 8th ed, 2017. Available from www.diabetesatlas.org/resources/2017-atlas.html. Accessed 15 March 2019 International Diabetes Federation (IDF) (2017) IDF diabetes atlas, 8th ed, 2017. Available from www.diabetesatlas.org/resources/2017-atlas.html. Accessed 15 March 2019
10.
go back to reference Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes (2017) Committee report: glycemic targets for elderly patients with diabetes. J Diabetes Investig 8:126–128CrossRef Japan Diabetes Society (JDS)/Japan Geriatrics Society (JGS) Joint Committee on Improving Care for Elderly Patients with Diabetes (2017) Committee report: glycemic targets for elderly patients with diabetes. J Diabetes Investig 8:126–128CrossRef
16.
go back to reference Petersen RC, Lopez O, Armstrong MJ et al (2018) Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90:126–135CrossRefPubMedPubMedCentral Petersen RC, Lopez O, Armstrong MJ et al (2018) Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90:126–135CrossRefPubMedPubMedCentral
27.
go back to reference The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRef The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRef
28.
go back to reference Areosa Sastre A, Vernooij RW, Gonzalez-Colaco Harmand M, Martinez G (2017) Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev (6):CD003804 Areosa Sastre A, Vernooij RW, Gonzalez-Colaco Harmand M, Martinez G (2017) Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev (6):CD003804
31.
go back to reference Sinclair AJ, Hillson R, Bayer AJ (2014) Diabetes and dementia in older people: a best clinical practice statement by a multidisciplinary National Expert Working Group. Diabet Med 31:1024–1031CrossRefPubMed Sinclair AJ, Hillson R, Bayer AJ (2014) Diabetes and dementia in older people: a best clinical practice statement by a multidisciplinary National Expert Working Group. Diabet Med 31:1024–1031CrossRefPubMed
32.
go back to reference de Galan BE, Zoungas S, Chalmers J et al (2009) Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52(11):2328–2336. https://doi.org/10.1007/s00125-009-1484-7 CrossRefPubMed de Galan BE, Zoungas S, Chalmers J et al (2009) Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 52(11):2328–2336. https://​doi.​org/​10.​1007/​s00125-009-1484-7 CrossRefPubMed
36.
go back to reference Koekkoek PS, Janssen J, Kooistra M et al (2016) Case-finding for cognitive impairment among people with type 2 diabetes in primary care using the test your memory and self-administered gerocognitive examination questionnaires: the Cog-ID study. Diabet Med 33(6):812–819. https://doi.org/10.1111/dme.12874 CrossRefPubMed Koekkoek PS, Janssen J, Kooistra M et al (2016) Case-finding for cognitive impairment among people with type 2 diabetes in primary care using the test your memory and self-administered gerocognitive examination questionnaires: the Cog-ID study. Diabet Med 33(6):812–819. https://​doi.​org/​10.​1111/​dme.​12874 CrossRefPubMed
Metadata
Title
Cognitive dysfunction in diabetes: how to implement emerging guidelines
Authors
Geert J. Biessels
Rachel A. Whitmer
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-019-04977-9

Other articles of this Issue 1/2020

Diabetologia 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.